Literature DB >> 28733443

Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.

Charles Dai1,2, Yoon-Mi Chung2, Evan Kovac2,3, Ziqi Zhu2, Jianneng Li2, Cristina Magi-Galluzzi4, Andrew J Stephenson3, Eric A Klein1,3, Nima Sharifi5,2,3,6.   

Abstract

Purpose: A major mechanism of castration-resistant prostate cancer (CRPC) involves intratumoral biosynthesis of dihydrotestosterone (DHT) from adrenal precursors. We have previously shown that adrenal-derived androstenedione (AD) is the preferred substrate over testosterone (T) for 5α-reductase expressed in metastatic CRPC, bypassing T as an obligate precursor to DHT. However, the metabolic pathway of adrenal-derived DHT biosynthesis has not been rigorously investigated in the setting of primary disease in the prostate.Experimental Design: Seventeen patients with clinically localized prostate cancer were consented for fresh tissues after radical prostatectomy. Prostate tissues were cultured ex vivo in media spiked with an equimolar mixture of AD and T, and stable isotopic tracing was employed to simultaneously follow the enzymatic conversion of both precursor steroids into nascent metabolites, detected by liquid chromatography-tandem mass spectrometry. CRPC cell line models and xenograft tissues were similarly assayed for comparative analysis. A tritium-labeled steroid radiotracing approach was used to validate our findings.
Results: Prostatectomy tissues readily 5α-reduced both T and AD. Furthermore, 5α-reduction of AD was the major directionality of metabolic flux to DHT. However, AD and T were comparably metabolized by 5α-reductase in primary prostate tissues, contrasting the preference exhibited by CRPC in which AD was favored over T. 5α-reductase inhibitors effectively blocked the conversion of AD to DHT.Conclusions: Both AD and T are substrates of 5α-reductase in prostatectomy tissues, resulting in two distinctly nonredundant metabolic pathways to DHT. Furthermore, the transition to CRPC may coincide with a metabolic switch toward AD as the favored substrate. Clin Cancer Res; 23(20); 6351-62. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28733443      PMCID: PMC5641243          DOI: 10.1158/1078-0432.CCR-17-1313

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  41 in total

1.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

Review 2.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

Review 3.  Steroid biosynthesis and prostate cancer.

Authors:  Nima Sharifi; Richard J Auchus
Journal:  Steroids       Date:  2012-04-05       Impact factor: 2.668

4.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Mahboubeh Papari-Zareei; Lori Watumull; Yan Daniel Zhao; Richard J Auchus; Nima Sharifi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-27       Impact factor: 11.205

5.  Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 and 2 by the Androgen Receptor in Prostate Cancer.

Authors:  Étienne Audet-Walsh; Tracey Yee; Ingrid S Tam; Vincent Giguère
Journal:  Endocrinology       Date:  2017-04-01       Impact factor: 4.736

Review 6.  Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.

Authors:  Lynn N Thomas; Robert C Douglas; Catherine B Lazier; Catherine K L Too; Roger S Rittmaster; Donald J Tindall
Journal:  Eur Urol       Date:  2007-11-05       Impact factor: 20.096

Review 7.  Androgen biosynthetic pathways in the human prostate.

Authors:  Van Luu-The; Alain Bélanger; Fernand Labrie
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-04       Impact factor: 4.690

8.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

9.  Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer.

Authors:  F Labrie; A Dupont; J Simard; V Luu-The; A Bélanger
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

Review 10.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

View more
  8 in total

Review 1.  Intracrinology-revisited and prostate cancer.

Authors:  Trevor M Penning; Andrea J Detlefsen
Journal:  J Steroid Biochem Mol Biol       Date:  2019-10-12       Impact factor: 4.292

2.  Prostate cancer: The pathway to progression: DHT biosynthesis.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2017-08-16       Impact factor: 14.432

3.  Hypoxia-Reoxygenation Couples 3βHSD1 Enzyme and Cofactor Upregulation to Facilitate Androgen Biosynthesis and Hormone Therapy Resistance in Prostate Cancer.

Authors:  Liang Qin; Yoon-Mi Chung; Michael Berk; Bryan Naelitz; Ziqi Zhu; Eric Klein; Abhishek A Chakraborty; Nima Sharifi
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

4.  Sex steroid modulation of macrophages within the prostate tumor microenvironment.

Authors:  Zohra Berrehail; Clovis Boibessot; Typhaine Gris; France-Hélène Joncas; Fanny Gaignier; Chantal Guillemette; Louis Lacombe; Yves Fradet; Paul Toren
Journal:  Am J Clin Exp Urol       Date:  2022-04-15

5.  Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion.

Authors:  Arja Kaipainen; Ailin Zhang; Rui M Gil da Costa; Jared Lucas; Brett Marck; Alvin M Matsumoto; Colm Morrissey; Lawrence D True; Elahe A Mostaghel; Peter S Nelson
Journal:  Prostate       Date:  2019-08-02       Impact factor: 4.104

Review 6.  Hormonal Therapy for Prostate Cancer.

Authors:  Kunal Desai; Jeffrey M McManus; Nima Sharifi
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

Review 7.  The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.

Authors:  Boris Y Shorning; Manisha S Dass; Matthew J Smalley; Helen B Pearson
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

8.  Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation.

Authors:  Jianneng Li; Michael Berk; Mohammad Alyamani; Navin Sabharwal; Christopher Goins; Joseph Alvarado; Mehdi Baratchian; Ziqi Zhu; Shaun Stauffer; Eric A Klein; Nima Sharifi
Journal:  Sci Transl Med       Date:  2021-05-26       Impact factor: 17.956

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.